Alyaa Al-Mughairy: Rethinking Emicizumab Low-Dose Regimens to Ensure Safe and Sustainable Patient Access
Alyaa Al-Mughairy, Pediatric Hematology Oncology Senior Consultant at Ministry of Health Oman,and National Oncology Centre at Royal Hospital, shared Michael Makris‘s post on LinkedIn, adding:
”While standard maintenance doses for Emicizumab in hemophilia A target high plasma concentrations, real-world clinical experience in low economic countries, including our own suggests a low-dose regimens can still effectively maintain a 0.0 Annual bleeding rate for spontaneous bleeds.
This suggests that for many, we may be dosing beyond what is strictly necessary for clinical efficacy based in the standard approved doses.
It’s time to re-consider low doses regimen, ensuring sustainable access driven model of care to all patients without compromising patient safety or posing burden on the healthcare system.”
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn:
”The approved dose of Hemlibra (emicizumab) is generous, and smaller doses are likely to be effective.
You can read the arguments in my commentary published in the current issue of the Journal of Thrombosis and Haemostasis.”
Title: Is all the approved emicizumab dose essential?
Author: Michael Makris
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 22, 2026, 05:59Harshdeep Singh: Why Platelet Counts Matter Less Than the Cause
-
Jun 22, 2026, 05:45Shakti Bedanta Mishra: A Practical Guide to Hematology in Critical Care
-
Jun 22, 2026, 05:29Tara Munn: The Human Experience of Immune Thrombocytopenia At Sanofi
-
Jun 22, 2026, 04:06Gaurav Gupta: Unlocking the Inflammatory Mechanisms of Hemorrhagic Stroke Recovery
-
Jun 22, 2026, 03:47Flora Peyvandi: Optimizing Plasma Transfusion in Cirrhosis
-
Jun 21, 2026, 23:55Arun V. J.: At ISBT, the Best Innovations Are Often Already Among Us
-
Jun 21, 2026, 23:38David Armstrong: Healing Ulcers Fast with Low Thrombosis Risk with Total-Contact Casts
-
Jun 21, 2026, 20:12Large Meta-Analysis Highlights Key Predictors of Major Bleeding With DOAC Therapy – JTH
-
Jun 21, 2026, 19:19Tribikram Panda: Ensuring Global Equity in Management of Sickle Cell Disease